A Phase I Dose-Escalation and Bioequivalence Study of a Trastuzumab Biosimilar in Healthy Male Volunteers
- 7 November 2014
- journal article
- research article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 34 (12) , 887-894
Abstract
Trastuzumab (Herceptin®) is a humanized monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2) and is used in the treatment of HER2-overexpressing breast and gastric cancer. FTMB is being developed as a biosimilar of trastuzumab. In this combined dose-escalation and bioequivalence study of parallel design, the pharmacokinetic profile of FTMB was compared with Herceptin®. Healthy male volunteers received single doses of 0.5, 1.5, 3.0 or 6.0 mg/kg FTMB, or placebo, in consecutive dose-escalation cohorts to assess the safety profile. Thereafter, the 6 mg/kg cohort was expanded to establish bioequivalence between FTMB (Test) and Herceptin® (Reference) based on an acceptance interval of 80.0–125.0 %. In total, 118 subjects were enrolled in the study. The mean area under the concentration–time curve from time zero to infinity (AUC∞) was 1,609 µg·day/mL (Test) and 1,330 µg·day/mL (Reference). The log-transformed geometric mean Test/Reference (T/R) ratio for AUC∞ was 89.6 % (90 % confidence interval [CI] 85.1–94.4), demonstrating bioequivalence. For the secondary endpoint, the maximum concentration observed (C max), the geometric mean T/R ratio was 89.4 % (90 % CI 83.4–95.9). Non-linear, target-mediated pharmacokinetics were also observed. Adverse events other than the documented side effects of Herceptin® (fever, influenza-like illness, and fatigue) did not occur. No signs of cardiotoxicity were observed. This bioequivalence study with a trastuzumab biosimilar in healthy male volunteers demonstrated bioequivalence of FTMB with Herceptin®. FTMB was well tolerated in doses up to 6 mg/kg. Non-linear target elimination was also observed in the pharmacokinetic profile of trastuzumab.Keywords
This publication has 11 references indexed in Scilit:
- Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2‐Positive Breast CancerThe Journal of Clinical Pharmacology, 2013
- Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast CancerClinical Pharmacology & Therapeutics, 2010
- Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)Journal of Clinical Oncology, 2009
- Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody TherapyThe Oncologist, 2008
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancerCancer Chemotherapy and Pharmacology, 2005
- Phase II Study of Efficacy, Safety, and Pharmacokinetics of Trastuzumab Monotherapy Administered on a 3-Weekly ScheduleJournal of Clinical Oncology, 2005
- Retrospective Analysis of the Safety of Herceptin® Immunotherapy in Metastatic Breast CancerOncology, 2001
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.Journal of Clinical Oncology, 1996